Product Description
AZD9898 is an orally active inhibitor of leukotriene C4 synthase (LTC4S) that was developed for the treatment of asthma
Mechanisms of Action: LTC4S Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Asthma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| D7620C00001 | P1 |
Terminated |
Asthma |
2017-08-23 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|